ImmuPharma plc (LON:IMM – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 3.30 and last traded at GBX 3.60, with a volume of 3904028 shares changing hands. The stock had previously closed at GBX 3.46.
ImmuPharma Price Performance
The business’s fifty day simple moving average is GBX 3.87 and its two-hundred day simple moving average is GBX 4.74. The company has a market cap of £22.46 million, a PE ratio of -9.73 and a beta of 3.01.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
